[go: up one dir, main page]

NO20081837L - Antineoplastiske kombinasjoner med MTOR inhibitor, herceptin og/eller HKI-272 - Google Patents

Antineoplastiske kombinasjoner med MTOR inhibitor, herceptin og/eller HKI-272

Info

Publication number
NO20081837L
NO20081837L NO20081837A NO20081837A NO20081837L NO 20081837 L NO20081837 L NO 20081837L NO 20081837 A NO20081837 A NO 20081837A NO 20081837 A NO20081837 A NO 20081837A NO 20081837 L NO20081837 L NO 20081837L
Authority
NO
Norway
Prior art keywords
hki
herceptin
mtor inhibitor
combination
antineoplastic combinations
Prior art date
Application number
NO20081837A
Other languages
English (en)
Inventor
Sridhar Krishna Rabindran
Laurence Moore
Charles M Zacharchuk
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37845244&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20081837(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NO20081837L publication Critical patent/NO20081837L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

SAMMENDRAG En kombinasjon av temsirolimus og herceptin ved behandling av kreft er gitt. En kombinasjon av temsirolimus og HKI-272 er gitt. En kombinasjon av herceptin og HKI-272 er også gitt. Regimer og sett for behandling av metastasisk brystkreft, inneholdende herceptin, temsirolimus og/eller HKI-272, eventuelt i kombinasjon med andre anti-neoplastiske midler eller immun-modulatorer er beskrevet.
NO20081837A 2005-11-04 2008-04-16 Antineoplastiske kombinasjoner med MTOR inhibitor, herceptin og/eller HKI-272 NO20081837L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US73356205P 2005-11-04 2005-11-04
US83750906P 2006-08-14 2006-08-14
PCT/US2006/042915 WO2007056118A1 (en) 2005-11-04 2006-11-02 Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272

Publications (1)

Publication Number Publication Date
NO20081837L true NO20081837L (no) 2008-07-30

Family

ID=37845244

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20081837A NO20081837L (no) 2005-11-04 2008-04-16 Antineoplastiske kombinasjoner med MTOR inhibitor, herceptin og/eller HKI-272

Country Status (17)

Country Link
US (6) US20070104721A1 (no)
EP (2) EP1942937A1 (no)
JP (7) JP2009514870A (no)
KR (1) KR101354828B1 (no)
CN (1) CN103110948A (no)
AR (1) AR057854A1 (no)
AU (1) AU2006311877A1 (no)
BR (1) BRPI0618042A2 (no)
CA (1) CA2626326C (no)
CR (1) CR9901A (no)
EC (1) ECSP088423A (no)
IL (1) IL190805A (no)
NO (1) NO20081837L (no)
PE (1) PE20070763A1 (no)
RU (2) RU2451524C2 (no)
TW (1) TW200803892A (no)
WO (1) WO2007056118A1 (no)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1848414T1 (sl) * 2005-02-03 2011-08-31 Gen Hospital Corp Postopek za zdravljenje raka, odpornega na gefitinib
US8802183B2 (en) 2005-04-28 2014-08-12 Proteus Digital Health, Inc. Communication system with enhanced partial power source and method of manufacturing same
DK1889198T3 (da) 2005-04-28 2015-02-09 Proteus Digital Health Inc Farma-informatiksystem
RU2451524C2 (ru) * 2005-11-04 2012-05-27 Вайет Противоопухолевые комбинации с ингибиторами mtor, герцептином и/или hki-272
KR20080108517A (ko) * 2006-04-05 2008-12-15 노파르티스 아게 암을 치료하기 위한 치료제의 조합물
US20100081681A1 (en) * 2006-08-16 2010-04-01 Blagosklonny Mikhail V Methods and compositions for preventing or treating age-related diseases
WO2008121467A2 (en) * 2007-02-28 2008-10-09 Dana-Farber Cancer Institute, Inc. Combination therapy for treating cancer
SI2132573T1 (sl) 2007-03-02 2014-07-31 Genentech, Inc. Napovedovanje odziva na inhibitor dimerizacije HER na osnovi nizke ekspresije HER3
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
WO2009054001A1 (en) * 2007-10-22 2009-04-30 Biocon Limited A pharmaceutical composition and a process thereof
CN102099025A (zh) * 2008-05-16 2011-06-15 马尔药品公司 Pm00104与另一抗肿瘤剂的联合疗法
CN101584696A (zh) * 2008-05-21 2009-11-25 上海艾力斯医药科技有限公司 包含喹唑啉衍生物的组合物及制备方法、用途
NZ590009A (en) * 2008-06-17 2012-08-31 Wyeth Llc Antineoplastic combinations containing hki-272 and vinorelbine
KR101434009B1 (ko) * 2008-08-04 2014-08-25 와이어쓰 엘엘씨 4-아닐리노-3-사이아노퀴놀린과 카페시타빈의 항신생물성 조합물
WO2010070117A1 (en) * 2008-12-18 2010-06-24 Universite Libre De Bruxelles Treatment method by the administration of anti-her2 targeted active compounds to patients with early breast cancer and her2-negative primary tumor
CN103989681A (zh) 2009-04-06 2014-08-20 惠氏有限责任公司 用于乳腺癌的利用奈拉替尼的治疗方案
WO2010118419A2 (en) * 2009-04-10 2010-10-14 Haiyan Qi Novel anti-aging agents and methods to identify them
US8545402B2 (en) 2009-04-28 2013-10-01 Proteus Digital Health, Inc. Highly reliable ingestible event markers and methods for using the same
WO2011056741A2 (en) * 2009-11-09 2011-05-12 Wyeth Llc Coated drug spheroids and uses thereof for eliminating or reducing conditions such as emesis and diarrhea
WO2011070499A1 (en) * 2009-12-11 2011-06-16 Wyeth Llc Phosphatidylinositol-3-kinase pathway biomarkers
EP2524231B1 (en) 2010-01-13 2017-06-28 Wyeth LLC A CUT-POINT IN PTEN PROTEIN EXPRESSION THAT ACCURATELY IDENTIFIES TUMORS AND IS PREDICTIVE OF DRUG RESPONSE TO A PAN-ErbB INHIBITOR
AU2011237612B2 (en) 2010-04-07 2016-05-12 Otsuka Pharmaceutical Co., Ltd. Miniature ingestible device
US9107806B2 (en) 2010-11-22 2015-08-18 Proteus Digital Health, Inc. Ingestible device with pharmaceutical product
US9756874B2 (en) 2011-07-11 2017-09-12 Proteus Digital Health, Inc. Masticable ingestible product and communication system therefor
WO2015112603A1 (en) 2014-01-21 2015-07-30 Proteus Digital Health, Inc. Masticable ingestible product and communication system therefor
TWI659994B (zh) 2013-01-29 2019-05-21 美商普羅托斯數位健康公司 高度可膨脹之聚合型薄膜及包含彼之組成物
US10175376B2 (en) 2013-03-15 2019-01-08 Proteus Digital Health, Inc. Metal detector apparatus, system, and method
TWI482782B (zh) 2013-05-31 2015-05-01 Univ Nat Chiao Tung 架接抗體之雙乳化核殼奈米結構
AU2014296032A1 (en) 2013-07-31 2016-03-17 Windward Pharma, Inc. Aerosol tyrosine kinase inhibitor compounds and uses thereof
US20180057603A1 (en) * 2013-08-09 2018-03-01 The Trustees Of The University Of Pennsylvania Combination of IFN-gamma with Anti-ERBB Antibody for the Treatment of Cancers
US11446516B2 (en) 2013-08-09 2022-09-20 The Trustees Of The University Of Pennsylvania Methods of increasing response to cancer radiation therapy
CN105828822B (zh) * 2013-08-14 2019-10-18 诺华股份有限公司 用于治疗癌症的组合疗法
US9796576B2 (en) 2013-08-30 2017-10-24 Proteus Digital Health, Inc. Container with electronically controlled interlock
US10084880B2 (en) 2013-11-04 2018-09-25 Proteus Digital Health, Inc. Social media networking based on physiologic information
US11051543B2 (en) 2015-07-21 2021-07-06 Otsuka Pharmaceutical Co. Ltd. Alginate on adhesive bilayer laminate film
CN109843149B (zh) 2016-07-22 2020-07-07 普罗秋斯数字健康公司 可摄入事件标记的电磁感测和检测
CA3041041A1 (en) 2016-10-26 2018-05-03 Proteus Digital Health, Inc. Methods for manufacturing capsules with ingestible event markers
TW201827050A (zh) * 2017-01-22 2018-08-01 大陸商江蘇恆瑞醫藥股份有限公司 Ｅｇｆｒ／ｈｅｒ２抑制劑聯合嘧啶類抗代謝藥物的用途
RU2648642C1 (ru) * 2017-06-06 2018-03-26 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ неоадъювантного лечения больных местно-распространенным раком шейки матки
JP7317343B2 (ja) * 2019-03-20 2023-07-31 公立大学法人大阪 乳がんの予防又は治療剤及び乳がん細胞の増殖抑制剤
WO2022076917A1 (en) * 2020-10-08 2022-04-14 Kumquat Biosciences Inc. Modulators of cell proliferation and uses thereof
GB202111193D0 (en) 2021-08-03 2021-09-15 Phoremost Ltd Pharmaceutical compounds
GB202311018D0 (en) 2023-07-19 2023-08-30 Sentinel Oncology Ltd Pharmaceutical compounds

Family Cites Families (218)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4316885A (en) 1980-08-25 1982-02-23 Ayerst, Mckenna And Harrison, Inc. Acyl derivatives of rapamycin
US4650803A (en) 1985-12-06 1987-03-17 University Of Kansas Prodrugs of rapamycin
CA1327358C (en) 1987-11-17 1994-03-01 Morio Fujiu Fluoro cytidine derivatives
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US5023264A (en) 1990-07-16 1991-06-11 American Home Products Corporation Rapamycin oximes
US5221670A (en) 1990-09-19 1993-06-22 American Home Products Corporation Rapamycin esters
US5233036A (en) 1990-10-16 1993-08-03 American Home Products Corporation Rapamycin alkoxyesters
US5120842A (en) 1991-04-01 1992-06-09 American Home Products Corporation Silyl ethers of rapamycin
US5100883A (en) 1991-04-08 1992-03-31 American Home Products Corporation Fluorinated esters of rapamycin
US5118678A (en) 1991-04-17 1992-06-02 American Home Products Corporation Carbamates of rapamycin
US5118677A (en) 1991-05-20 1992-06-02 American Home Products Corporation Amide esters of rapamycin
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
US5162333A (en) 1991-09-11 1992-11-10 American Home Products Corporation Aminodiesters of rapamycin
US5177203A (en) 1992-03-05 1993-01-05 American Home Products Corporation Rapamycin 42-sulfonates and 42-(N-carboalkoxy) sulfamates useful as immunosuppressive agents
US5256790A (en) 1992-08-13 1993-10-26 American Home Products Corporation 27-hydroxyrapamycin and derivatives thereof
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5489680A (en) 1992-10-13 1996-02-06 American Home Products Corporation Carbamates of rapamycin
US5480989A (en) 1992-10-13 1996-01-02 American Home Products Corporation Carbamates of rapamycin
US5302584A (en) 1992-10-13 1994-04-12 American Home Products Corporation Carbamates of rapamycin
US5411967A (en) 1992-10-13 1995-05-02 American Home Products Corporation Carbamates of rapamycin
US5480988A (en) 1992-10-13 1996-01-02 American Home Products Corporation Carbamates of rapamycin
US5434260A (en) 1992-10-13 1995-07-18 American Home Products Corporation Carbamates of rapamycin
US5262423A (en) 1992-10-29 1993-11-16 American Home Products Corporation Rapamycin arylcarbonyl and alkoxycarbonyl carbamates as immunosuppressive and antifungal agents
US5258389A (en) 1992-11-09 1993-11-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
US5260300A (en) 1992-11-19 1993-11-09 American Home Products Corporation Rapamycin carbonate esters as immuno-suppressant agents
TW254946B (no) 1992-12-18 1995-08-21 Hoffmann La Roche
AU671491B2 (en) 1992-12-18 1996-08-29 F. Hoffmann-La Roche Ag N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines
US5504091A (en) 1993-04-23 1996-04-02 American Home Products Corporation Biotin esters of rapamycin
US5391730A (en) 1993-10-08 1995-02-21 American Home Products Corporation Phosphorylcarbamates of rapamycin and oxime derivatives thereof
US5373014A (en) 1993-10-08 1994-12-13 American Home Products Corporation Rapamycin oximes
US5378836A (en) 1993-10-08 1995-01-03 American Home Products Corporation Rapamycin oximes and hydrazones
US5385910A (en) 1993-11-22 1995-01-31 American Home Products Corporation Gem-distributed esters of rapamycin
US5385909A (en) 1993-11-22 1995-01-31 American Home Products Corporation Heterocyclic esters of rapamycin
US5385908A (en) 1993-11-22 1995-01-31 American Home Products Corporation Hindered esters of rapamycin
US5389639A (en) 1993-12-29 1995-02-14 American Home Products Company Amino alkanoic esters of rapamycin
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US5463048A (en) 1994-06-14 1995-10-31 American Home Products Corporation Rapamycin amidino carbamates
TW398975B (en) 1994-07-22 2000-07-21 Lilly Co Eli Pharmaceutical composition for inhibiting bone loss
US5476932A (en) 1994-08-26 1995-12-19 Hoffmann-La Roche Inc. Process for producing N4-acyl-5'-deoxy-5-fluorocytidine derivatives
US5491231A (en) 1994-11-28 1996-02-13 American Home Products Corporation Hindered N-oxide esters of rapamycin
US5563145A (en) 1994-12-07 1996-10-08 American Home Products Corporation Rapamycin 42-oximes and hydroxylamines
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9508565D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
US5705151A (en) 1995-05-18 1998-01-06 National Jewish Center For Immunology & Respiratory Medicine Gene therapy for T cell regulation
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
JP3437685B2 (ja) 1995-09-12 2003-08-18 株式会社東芝 交直変換装置の制御保護システム
EP0860433B1 (en) 1995-11-07 2002-07-03 Kirin Beer Kabushiki Kaisha Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of growth factor receptor originating in platelet and pharmaceutical compositions containing the same
US5780462A (en) 1995-12-27 1998-07-14 American Home Products Corporation Water soluble rapamycin esters
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
WO1998002441A2 (en) 1996-07-12 1998-01-22 Ariad Pharmaceuticals, Inc. Non immunosuppressive antifungal rapalogs
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
US6426383B1 (en) 1997-05-28 2002-07-30 Nalco Chemical Company Preparation of water soluble polymer dispersions from vinylamide monomers
US6251912B1 (en) 1997-08-01 2001-06-26 American Cyanamid Company Substituted quinazoline derivatives
TW557297B (en) 1997-09-26 2003-10-11 Abbott Lab Rapamycin analogs having immunomodulatory activity, and pharmaceutical compositions containing same
EA004436B1 (ru) 1998-09-29 2004-04-29 Уайт Холдингз Корпорейшн Замещенные 3-цианохинолины в качестве ингибиторов протеинтирозинкиназ
US6288082B1 (en) * 1998-09-29 2001-09-11 American Cyanamid Company Substituted 3-cyanoquinolines
US6297258B1 (en) 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
US6432979B1 (en) 1999-08-12 2002-08-13 American Cyanamid Company Method of treating or inhibiting colonic polyps and colorectal cancer
EP1212331B1 (en) 1999-08-24 2004-04-21 Ariad Gene Therapeutics, Inc. 28-epirapalogs
TWI256395B (en) 1999-09-29 2006-06-11 Wyeth Corp Regioselective synthesis of rapamycin derivatives
US6277983B1 (en) * 2000-09-27 2001-08-21 American Home Products Corporation Regioselective synthesis of rapamycin derivatives
MXPA02006660A (es) 2000-01-07 2002-12-13 Transform Pharmaceuticals Inc Formacion, identificacion y analisis de diversas formas solidas de alto rendimiento.
US6384051B1 (en) 2000-03-13 2002-05-07 American Cyanamid Company Method of treating or inhibiting colonic polyps
TWI310684B (en) 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
GB0008368D0 (en) 2000-04-06 2000-05-24 Astrazeneca Ab Combination product
US7306801B2 (en) * 2000-05-15 2007-12-11 Health Research, Inc. Methods of therapy for cancers characterized by overexpression of the HER2 receptor protein
ATE278421T1 (de) * 2000-08-11 2004-10-15 Wyeth Corp Verfahren zur behandlung eines östrogenrezeptor positives karzinoms
TWI286074B (en) * 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
TWI296196B (en) 2001-04-06 2008-05-01 Wyeth Corp Antineoplastic combinations
EP1385551B1 (en) * 2001-04-06 2008-09-03 Wyeth Antineoplastic combinations comprising cci-779 (rapamycin derivative) together with gemcitabine or fluorouracil
TWI233359B (en) 2001-04-06 2005-06-01 Wyeth Corp Pharmaceutical composition for treating neoplasm
PT1392313E (pt) * 2001-05-16 2007-07-17 Novartis Ag Combinação que compreende n - ( 5- [ 4- ( metil-piperazinomrtil ) - benxoilamido ] - 2 -metilfenil ) - 4 -( 3 - piridil ) - 2 - pirimidina-amina e um agente quimioterapêutico
ZA200603888B (en) 2001-06-01 2007-05-30 Wyeth Corp Antineoplastic combinations
BR0210101A (pt) 2001-06-01 2004-06-08 Wyeth Corp Combinações antineoplásticas
EP1466174B1 (en) 2001-06-14 2009-05-13 The Regents of the University of California Mutations in the bcr-abl tyrosine kinase associated with resistance to sti-571
UA77200C2 (en) * 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
US6821988B2 (en) 2001-11-27 2004-11-23 Wyeth Holdings Corporation 3-cyanoquinolines as inhibitors of EGF-R and HER2 kinases
ES2485841T3 (es) * 2002-02-01 2014-08-14 Ariad Pharmaceuticals, Inc Compuestos que contienen fósforo y usos de los mismos
TWI275390B (en) 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles
WO2003106622A2 (en) * 2002-05-30 2003-12-24 The Children's Hospital Of Philadelphia Methods for treatment of acute lymphocytic leukemia
BR0311814A (pt) 2002-06-05 2005-03-15 Cedars Sinai Medical Center Método de tratar câncer empregando inibidores de cinase
US20060094674A1 (en) * 2002-07-05 2006-05-04 Neel Benjamin G Combination of mtor inhibitor and a tyrosine kinase inhibitor for the treatment of neoplasms
DE60319118T2 (de) 2002-07-30 2009-02-05 Wyeth Parenterale formulierungen mit einem rapamycin hydroxyester
RU2326654C2 (ru) 2002-09-17 2008-06-20 Уайт Пероральные композиции
US20040209930A1 (en) 2002-10-02 2004-10-21 Carboni Joan M. Synergistic methods and compositions for treating cancer
CL2004000016A1 (es) 2003-01-21 2005-04-15 Wyeth Corp Compuesto derivado de cloruro de 4-amino-2-butenoilo o una sal farmaceuticamente aceptable del mismo; procedimiento para preparar dicho compuesto, util como intermediario en la sintesis de compuestos inhibidores de proteina quinasa tirosina.
CN1437942A (zh) 2003-02-08 2003-08-27 杭州华卫制药技术开发有限公司 注射用长春瑞滨粉针剂及制备方法
UA83484C2 (uk) 2003-03-05 2008-07-25 Уайт Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
RU2005136222A (ru) * 2003-04-22 2006-03-20 Уайт (Us) Противоопухолевые комбинации
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
EA010485B1 (ru) 2003-07-23 2008-10-30 Байер Фамэсьютиклс Копэрейшн Производное n,n'-дифенилмочевины, фармацевтическая композиция (варианты) и способ лечения и предупреждения заболеваний и состояний с его использованием (варианты)
US20050025825A1 (en) 2003-07-31 2005-02-03 Xanodyne Pharmacal, Inc. Tranexamic acid formulations with reduced adverse effects
US20050026933A1 (en) 2003-08-01 2005-02-03 Wyeth Holdings Corporation Use of a combination of an epidermal growth factor receptor kinase inhibitor and cytotoxic agents for treatment and inhibition of cancer
KR20060057605A (ko) 2003-08-07 2006-05-26 와이어쓰 Ｃｃｉ-779의 위치선택적 합성 방법
CN1835923A (zh) 2003-08-19 2006-09-20 惠氏控股公司 制备4－氨基－3－喹啉腈的方法
US7399865B2 (en) * 2003-09-15 2008-07-15 Wyeth Protein tyrosine kinase enzyme inhibitors
EP1670473A1 (en) 2003-09-15 2006-06-21 Wyeth a Corporation of the State of Delaware Substituted quinolines as protein tyrosine kinase enzyme inhibitors
TWI372066B (en) 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
US20050142192A1 (en) 2003-10-15 2005-06-30 Wyeth Oral administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl] phosphonic acid and derivatives
WO2005049021A1 (en) 2003-11-03 2005-06-02 Oy Helsinki Transplantation R & D Ltd Materials and methods for inhibiting neointimal hyperplasia
WO2005044091A2 (en) 2003-11-05 2005-05-19 Board Of Regents, The University Of Texas System Diagnostic and therapeutic methods and compositions involving pten and breast cancer
TW200526684A (en) * 2003-11-21 2005-08-16 Schering Corp Anti-IGFR1 antibody therapeutic combinations
US7235564B2 (en) 2003-12-04 2007-06-26 Amr Technology, Inc. Vinorelbine derivatives
US9016221B2 (en) 2004-02-17 2015-04-28 University Of Florida Research Foundation, Inc. Surface topographies for non-toxic bioadhesion control
AR047988A1 (es) * 2004-03-11 2006-03-15 Wyeth Corp Combinaciones antineoplásicas de cci-779 y rituximab
PT1733056E (pt) 2004-03-31 2013-08-29 Gen Hospital Corp Método para determinar a responsividade do cancro a tratamentos visando o receptor do factor de crescimento epidérmico
AU2005250484B2 (en) 2004-06-04 2011-08-11 Genentech, Inc. EGFR mutations
EP1781815A2 (en) 2004-07-23 2007-05-09 AstraZeneca AB Method of predicting the responsiveness of a tumour to erbb receptor drugs
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
TW200616612A (en) 2004-10-08 2006-06-01 Wyeth Corp Method for the teatment of polycystic kidney disease field of invention
TW200626610A (en) * 2004-10-13 2006-08-01 Wyeth Corp Analogs of 17-hydroxywortmannin as PI3K inhibitors
US20080254497A1 (en) 2004-10-15 2008-10-16 Monogram Biosciences, Inc. Response Predictors for Erbb Pathway-Specific Drugs
US20060084666A1 (en) 2004-10-18 2006-04-20 Harari Paul M Combined treatment with radiation and an epidermal growth factor receptor kinase inhibitor
WO2006085168A2 (en) 2005-01-07 2006-08-17 Ranbaxy Laboratories Limited Solid oral dosage forms of ziprasidone containing colloidal silicone dioxide
GB0501999D0 (en) 2005-02-01 2005-03-09 Sentinel Oncology Ltd Pharmaceutical compounds
SI1848414T1 (sl) 2005-02-03 2011-08-31 Gen Hospital Corp Postopek za zdravljenje raka, odpornega na gefitinib
WO2006081985A1 (en) 2005-02-04 2006-08-10 F. Hoffmann-La Roche Ag Combined treatment with an n4-(substituted-oxycarbonyl)-5’-deoxy-5-fluorocytidine derivative and an epidermal growth factor receptor kinase inhibitor
DE602006021401D1 (de) 2005-02-28 2011-06-01 Eisai R&D Man Co Ltd Neue kombinierte anwendung einer sulfonamid-verbindung zur behandlung von krebs
CA2610343A1 (en) 2005-03-03 2006-09-08 Takeda Pharmaceutical Company Limited Release-control composition
CA2599445C (en) 2005-03-09 2022-05-03 Abbott Laboratories Diagnostics method for identifying candidate patients for the treatment with trastuzumab
GB0504994D0 (en) * 2005-03-11 2005-04-20 Biotica Tech Ltd Novel compounds
US20060235006A1 (en) 2005-04-13 2006-10-19 Lee Francis Y Combinations, methods and compositions for treating cancer
JP2008536847A (ja) * 2005-04-14 2008-09-11 ワイス ゲフィニチブ耐性患者における上皮増殖因子レセプター（ｅｇｆｒ）キナーゼインヒビターの使用
WO2006116016A2 (en) 2005-04-21 2006-11-02 The Regents Of The University Of California Molecular determinants of egfr kinase inhibitor response in glioblastoma
AR056328A1 (es) 2005-04-28 2007-10-03 Wyeth Corp TANAPROGET MICRONIZADO, COMPOSICIONES Y MÉTODOS PARA SU PREPARACIoN
AU2006245421A1 (en) 2005-05-12 2006-11-16 Pfizer Inc. Anticancer combination therapy using sunitinib malate
AU2006249598A1 (en) 2005-05-25 2006-11-30 Wyeth Methods of preparing 3-cyano-quinolines and intermediates made thereby
KR20080016671A (ko) 2005-05-25 2008-02-21 와이어쓰 치환된 3-시아노퀴놀린 및 그것의 중간체를 합성하는 방법
DE102005053679A1 (de) 2005-06-24 2006-12-28 Bayer Healthcare Ag Therapeutischer Einsatz von Moxifloxacin zur Rekonstruktion von Funktionsstörungen des Immunsystems
PE20070192A1 (es) 2005-07-15 2007-03-16 Wyeth Corp Formas de dosificacion de liberacion retardada oral altamente biodisponibles de succinato de o-desmetilvenlafaxina
EP1925941B1 (en) 2005-08-01 2012-11-28 Eisai R&D Management Co., Ltd. Method for prediction of the efficacy of vascularization inhibitor
WO2007015578A1 (ja) 2005-08-02 2007-02-08 Eisai R & D Management Co., Ltd. 血管新生阻害物質の効果を検定する方法
AU2005337051A1 (en) 2005-10-05 2007-04-12 Astrazeneca Uk Limited Method to predict or monitor the response of a patient to an ErbB receptor drug
WO2007050495A2 (en) 2005-10-26 2007-05-03 Children's Medical Center Corporation Method to prognose response to anti-egfr therapeutics
RU2451524C2 (ru) 2005-11-04 2012-05-27 Вайет Противоопухолевые комбинации с ингибиторами mtor, герцептином и/или hki-272
TW200803842A (en) 2005-11-04 2008-01-16 Wyeth Corp Antineoplastic combinations of temsirolimus and sunitinib malate
ES2412879T3 (es) 2005-11-11 2013-07-12 Boehringer Ingelheim International Gmbh Tratamiento combinado del cáncer que comprende inhibidores de EGFR/HER2
PT1951274E (pt) 2005-11-24 2009-12-14 Aicuris Gmbh & Co Kg Parapoxvírus em combinação com agentes quimioterapêuticos citotóxicos clássicos como bioquimioterapia para o tratamento de cancro
JP2007145745A (ja) 2005-11-25 2007-06-14 Osaka Univ 変異型ＥＧＦＲ下流シグナルを抑制するＳｒｃファミリーチロシンキナーゼ阻害剤を含む肺癌治療剤およびその利用
WO2007075794A2 (en) 2005-12-22 2007-07-05 Wyeth Oral formulations comprising tigecycline
WO2007095038A2 (en) 2006-02-09 2007-08-23 Novartis Ag Mutations and polymorphisms of erbb2
EP2010182A2 (en) 2006-04-07 2009-01-07 Novartis AG Use of c-src inhibitors in combination with a pyrimidylaminobenzamide compound for the treatment of leukemia
TW200806282A (en) 2006-05-05 2008-02-01 Wyeth Corp Solid dosage formulations
EP2032980A4 (en) 2006-05-18 2012-01-04 Molecular Profiling Inst Inc SYSTEM AND METHOD FOR DETERMINING INDIVIDUALIZED MEDICAL USE AGAINST A SICKNESS STATE
TW200808728A (en) 2006-05-23 2008-02-16 Wyeth Corp Method of preparing 4-halogenated quinoline intermediates
EP2405270B1 (en) 2006-06-30 2013-07-17 Merck Sharp & Dohme Corp. IGFBP2-Biomarker
SI2068880T1 (sl) 2006-09-18 2012-08-31 Boehringer Ingelheim Int Postopek za zdravljenje raka, ki vsebuje mutacije EGFR
AU2007305423A1 (en) 2006-09-28 2008-04-10 Follica, Inc. Methods, kits, and compositions for generating new hair follicles and growing hair
US20090317456A1 (en) 2006-10-13 2009-12-24 Medigene Ag Use of oncolytic viruses and antiangiogenic agents in the treatment of cancer
EP2121018A2 (en) 2006-12-13 2009-11-25 Schering Corporation Treating cancer with anti-igf1r antibody 19d12=sch 717454
CA2672828A1 (en) 2006-12-13 2008-06-26 Schering Corporation Methods of treatment
JP5311673B2 (ja) 2006-12-14 2013-10-09 エグゼリクシス， インコーポレイテッド Ｍｅｋ阻害剤の使用方法
WO2008076143A1 (en) 2006-12-18 2008-06-26 Osi Pharmaceuticals, Inc. Combination of igfr inhibitor and anti-cancer agent
NZ577798A (en) 2006-12-21 2012-04-27 Vertex Pharma 5-cyano-4- (pyrrolo [2, 3b] pyridine-3-yl) -pyrimidine derivatives useful as protein kinase inhibitors
CN101631536A (zh) 2007-01-12 2010-01-20 惠氏公司 片中片组合物
ES2609094T3 (es) 2007-01-25 2017-04-18 Dana-Farber Cancer Institute, Inc. Uso de anticuerpos anti-EGFR en el tratamiento de enfermedades mediadas por un EGFR mutante
CA2677193C (en) 2007-02-01 2015-06-30 Takeda Pharmaceutical Company Limited Tablet preparation without causing a tableting trouble
WO2008121467A2 (en) 2007-02-28 2008-10-09 Dana-Farber Cancer Institute, Inc. Combination therapy for treating cancer
GB0706633D0 (en) 2007-04-04 2007-05-16 Cyclacel Ltd Combination
EP1978106A1 (en) 2007-04-07 2008-10-08 Universitätsklinikum Hamburg-Eppendorf Detection of ESR1 amplification in endometrium cancer and ovary cancer
WO2008127710A2 (en) 2007-04-13 2008-10-23 Dana Farber Cancer Institute Methods for treating cancer resistant to erbb therapeutics
MX2009011228A (es) 2007-04-19 2009-11-02 Wellstat Biologics Corp Deteccion de niveles elevados de la proteina her-2/neu de celulas cancerosas circulantes no aisladas y tratamiento.
WO2008136838A1 (en) 2007-05-04 2008-11-13 Trustees Of Dartmouth College Novel amide derivatives of cddo and methods of use thereof
US20110014117A1 (en) 2007-06-28 2011-01-20 Schering Corporation Anti-igf1r
HRP20160430T1 (hr) 2007-09-10 2016-05-20 Boston Biomedical, Inc. Nova grupa inhibitora stat3 puta i inhibitora puta matičnih stanica karcinoma
JP2010540459A (ja) 2007-09-24 2010-12-24 トラガラ ファーマシューティカルズ，インク． Ｃｏｘ‐２阻害薬及びｅｇｆｒ［ｅｒｂｂ１］とｈｅｒ‐２［ｅｒｂｂ２］の二重阻害薬を用いた癌を治療するための併用療法
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
EP2212432A4 (en) 2007-10-22 2011-10-19 Schering Corp COMPLETELY HUMAN ANTI-VEGF ANTIBODIES AND USE PROCEDURES
EP2214770A4 (en) 2007-11-05 2011-01-05 Puretech Ventures METHODS, KITS AND COMPOSITIONS FOR ADMINISTERING PHARMACEUTICAL COMPOUNDS
CN101185633A (zh) 2007-12-14 2008-05-28 山东蓝金生物工程有限公司 一种治疗实体肿瘤的尼拉替尼缓释植入剂
EP2247757A2 (en) 2007-12-18 2010-11-10 Schering Corporation Biomarkers for sensitivity to anti-igf1r therapy
US20100297118A1 (en) 2007-12-27 2010-11-25 Macdougall John Therapeutic Cancer Treatments
WO2009100176A2 (en) 2008-02-07 2009-08-13 Abbott Laboratories Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
WO2009105234A2 (en) 2008-02-19 2009-08-27 Combinatorx, Incorporated Methods and compositions for the treatment of disorders associated with defects of the cystic fibrosis transmembrane conductance regulator gene or protein
WO2009108637A1 (en) 2008-02-25 2009-09-03 Prometheus Laboratories, Inc. Drug selection for breast cancer therapy using antibody-based arrays
WO2009111073A2 (en) 2008-03-06 2009-09-11 Odyssey Thera, Inc. High-content and high throughput assays for identification of lipid-regulating pathways, and novel therapeutic agents for lipid disorders
JP2011515478A (ja) 2008-03-25 2011-05-19 シェーリング コーポレイション 結腸直腸がんを処置または予防するための方法
US8741861B2 (en) 2008-03-27 2014-06-03 Vascular Biosciences Methods of novel therapeutic candidate identification through gene expression analysis in vascular-related diseases
US20090246198A1 (en) 2008-03-31 2009-10-01 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors and methods of use thereof
CA2725390C (en) 2008-04-08 2014-09-23 Syndax Pharmaceuticals, Inc. Use of a hdac inhibitor and a her-2 inhibitor in the treatment of breast cancer
CN102083442B (zh) 2008-04-18 2014-08-13 里亚塔医药公司 抗氧化剂炎症调节剂：在c-17具有氨基和其它修饰的齐墩果酸衍生物
WO2009146216A2 (en) 2008-04-18 2009-12-03 Reata Pharmaceuticals. Inc. Antioxidant inflammation modulators: novel derivatives of oleanolic acid
EP2279197B1 (en) 2008-04-18 2014-11-05 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the c-ring
SI2271658T1 (sl) 2008-04-18 2017-03-31 Reata Pharmaceuticals, Inc. Antioksidantni modulatorji vnetja: C-17 homologirani derivati oleanolne kisline
CA2721665C (en) 2008-04-18 2017-01-24 Reata Pharmaceuticals, Inc. Compounds including an anti-inflammatory pharmacore and methods of use
MX2010012064A (es) 2008-05-05 2010-12-06 Schering Corp Uso secuencial de agentes quimioterapeuticos citotoxicos para el tratamiento de cancer.
WO2009151910A2 (en) 2008-05-25 2009-12-17 Wyeth Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer
NZ590009A (en) 2008-06-17 2012-08-31 Wyeth Llc Antineoplastic combinations containing hki-272 and vinorelbine
ES2449396T3 (es) 2008-07-22 2014-03-19 Trustees Of Dartmouth College Cianoenonas monocíclicas y métodos de uso de las mismas
KR101434009B1 (ko) 2008-08-04 2014-08-25 와이어쓰 엘엘씨 4-아닐리노-3-사이아노퀴놀린과 카페시타빈의 항신생물성 조합물
WO2010030835A2 (en) 2008-09-11 2010-03-18 Wyeth Llc Pharmaceutical compositions of an src kinase inhibitor and an aromatase inhibitor
EP3075864A1 (en) 2008-10-14 2016-10-05 Caris MPI, Inc. Gene and gene expressed protein targets depicting biomarker patterns and signature sets by tumor type
WO2010048477A2 (en) 2008-10-24 2010-04-29 Wyeth Llc Improved process for preparation of coupled products from 4-amino-3-cyanoquinolines using stabilized intermediates
AU2009313510A1 (en) 2008-11-07 2010-05-14 Enzon Pharmaceuticals, Inc. ERBB-3 (HER3)-selective combination therapy
WO2010085845A1 (en) 2009-01-28 2010-08-05 The University Of Queensland Cancer therapy and/or diagnosis
EP2393364A4 (en) 2009-02-04 2013-03-13 Bipar Sciences Inc TREATMENT OF LUNG CANCER WITH A PARP INHIBITOR IN COMBINATION WITH A GROWTH FACTOR INHIBITOR
WO2010098627A2 (ko) 2009-02-27 2010-09-02 한올바이오파마주식회사 약제학적 제제
BRPI1011505A2 (pt) 2009-03-11 2016-03-22 Auckland Uniservices Ltd formas de pró-drogas de inibidores de quinase e sua aplicação em terapia
CN103989681A (zh) 2009-04-06 2014-08-20 惠氏有限责任公司 用于乳腺癌的利用奈拉替尼的治疗方案
AR076053A1 (es) 2009-04-14 2011-05-18 Schering Corp Derivados de pirazolo[1,5-a]pirimidina como inhibidores de mtor
WO2010124009A2 (en) 2009-04-21 2010-10-28 Schering Corporation Fully human anti-vegf antibodies and methods of using
US9908884B2 (en) 2009-05-05 2018-03-06 Dana-Farber Cancer Institute, Inc. EGFR inhibitors and methods of treating disorders
AU2010266342A1 (en) 2009-07-02 2012-01-19 Wyeth Llc 3-cyanoquinoline tablet formulations and uses thereof
WO2011008053A2 (ko) 2009-07-17 2011-01-20 한올바이오파마주식회사 Ｎ,ｎ-디메틸 이미도디카르본이미딕 디아미드의 프로피온산염, 이의 제조방법, 이를 포함하는 약제학적 조성물 및 이를 포함하는 복합제제
WO2011008054A2 (ko) 2009-07-17 2011-01-20 한올바이오파마주식회사 Ｎ,ｎ-디메틸 이미도디카르본이미딕 디아미드의 부틸산염, 이의 제조방법, 이를 포함하는 약제학적 조성물 및 이를 포함하는 복합제제
KR101211227B1 (ko) 2009-08-25 2012-12-11 한올바이오파마주식회사 메트포르민 아스코르브산염, 그의 제조방법, 그를 포함하는 약학 조성물 및 그를 포함하는 복합제제
KR20110021691A (ko) 2009-08-25 2011-03-04 한올바이오파마주식회사 메트포르민 메탄설폰산염, 그의 제조방법, 그를 포함하는 약학 조성물 및 그를 포함하는 복합제제
WO2011025269A2 (ko) 2009-08-25 2011-03-03 한올바이오파마주식회사 메트포르민 타우린염, 그의 제조방법, 그를 포함하는 약학 조성물 및 그를 포함하는 복합제제
US20110055838A1 (en) 2009-08-28 2011-03-03 Moyes William A Optimized thread scheduling via hardware performance monitoring
CA2775155A1 (en) 2009-10-01 2011-04-07 Csl Limited Method of treatment of philadelphia chromosome positive leukemia
DK4066821T3 (da) 2009-11-09 2025-04-14 Wyeth Llc Tabletformuleringer af neratinibmaleat
WO2011056741A2 (en) 2009-11-09 2011-05-12 Wyeth Llc Coated drug spheroids and uses thereof for eliminating or reducing conditions such as emesis and diarrhea
PL2719708T3 (pl) 2009-11-13 2018-04-30 Daiichi Sankyo Europe Gmbh Materiał i sposoby leczenia lub zapobiegania chorobom związanym z HER-3
WO2011069962A1 (en) 2009-12-07 2011-06-16 Boehringer Ingelheim International Gmbh Bibw 2992 for use in the treatment of triple negative breast cancer
WO2011070499A1 (en) 2009-12-11 2011-06-16 Wyeth Llc Phosphatidylinositol-3-kinase pathway biomarkers
EP2524231B1 (en) 2010-01-13 2017-06-28 Wyeth LLC A CUT-POINT IN PTEN PROTEIN EXPRESSION THAT ACCURATELY IDENTIFIES TUMORS AND IS PREDICTIVE OF DRUG RESPONSE TO A PAN-ErbB INHIBITOR

Also Published As

Publication number Publication date
IL190805A0 (en) 2008-11-03
RU2451524C2 (ru) 2012-05-27
US20070104721A1 (en) 2007-05-10
KR20080064156A (ko) 2008-07-08
JP2018203783A (ja) 2018-12-27
JP5952679B2 (ja) 2016-07-13
ECSP088423A (es) 2008-06-30
US20230201155A1 (en) 2023-06-29
AR057854A1 (es) 2007-12-19
JP2016128524A (ja) 2016-07-14
CR9901A (es) 2008-07-29
CN103110948A (zh) 2013-05-22
BRPI0618042A2 (pt) 2011-08-16
JP6040303B2 (ja) 2016-12-07
JP2009514870A (ja) 2009-04-09
JP6232463B2 (ja) 2017-11-15
IL190805A (en) 2011-08-31
RU2012100913A (ru) 2013-07-20
US20090297519A1 (en) 2009-12-03
US20140050721A1 (en) 2014-02-20
US20220354820A1 (en) 2022-11-10
JP6522056B2 (ja) 2019-05-29
JP2016041767A (ja) 2016-03-31
AU2006311877A1 (en) 2007-05-18
RU2008115454A (ru) 2009-12-10
RU2632104C2 (ru) 2017-10-02
KR101354828B1 (ko) 2014-02-18
JP2014098040A (ja) 2014-05-29
JP2017171693A (ja) 2017-09-28
JP2012214521A (ja) 2012-11-08
PE20070763A1 (es) 2007-08-08
WO2007056118A1 (en) 2007-05-18
CA2626326C (en) 2021-02-16
US10729672B2 (en) 2020-08-04
CA2626326A1 (en) 2007-05-18
TW200803892A (en) 2008-01-16
EP1942937A1 (en) 2008-07-16
EP3488866A1 (en) 2019-05-29
US20120308560A1 (en) 2012-12-06

Similar Documents

Publication Publication Date Title
NO20081837L (no) Antineoplastiske kombinasjoner med MTOR inhibitor, herceptin og/eller HKI-272
NO20084546L (no) Diagnostikk og behandlinger for tumorer
IL258880A (en) Diarylhydantoin compounds
PT2310011E (pt) Combinações antineoplásicas contendo hki-272 e vinorelbina
TW200501960A (en) Synergistic kits and compositions for treating cancer
IL182423A0 (en) Disubstituted pyrazolobenzodiazepines useful as inhibitors for cdk2 and angiogesis, and for the treatment of breast, colon, lung and prostate cancer
EP2298304A3 (en) Carboline derivatives useful in the treatment of cancer
MY148491A (en) FUSED BICYCLIC mTOR INHIBITORS
ECSP099523A (es) Antagonistas específicos de VEGF para terapia adyuvante y neoadyuvante y el tratamiento de tumores en estadíos tempranos
NO20070782L (no) Tetrapeptidanaloger.
NO20072179L (no) Kombinasjon av en SRC kinase inhibitor og en. BCR-ABL inhibitor for behandling av proleferative sykdommer
CY1118602T1 (el) Αντινεοπλασματικοι συνδυασμοι 4-ανιλινο-3-κυανοκινολινων και καπεσιταβινης
MX2019008701A (es) Terapia de combinacion que involucra compuestos macrociclicos de diarilo.
NZ590550A (en) Inhibitors of Apoptosis (IAP) for treating cancer
AR058505A1 (es) Combinaciones antineoplasicas de temsirolimus y malato de sunitinib
EA200801428A1 (ru) Производные пиридиазинона для лечения опухолей
DK1861509T3 (da) Fremgangsmåde til forudsigelse af progressionsfri og overordnet overlevelse for hvert opfølgningstidspunkt under behandling af patienter med metastatisk brystkræft under anvendelse af cirkulerende tumorceller
MX2008015775A (es) Compuestos y composiciones para tratamiento de cancer.
NO20082425L (no) Formuleringer omfattende jorumycin-, reni-eramycin-, safracin- eller saframycin-relaterte forbindelser for behandling av proliferative sykdommer
PT4419526T (pt) Compostos heterocíclicos para utilização no tratamento de cancro
DK1845990T3 (da) Behandling af metastaserede tumorer
CY1116492T1 (el) Δραστηριοτητα του τεμσιρολιμου κατα των ογκων στον καρκινο θηλοειδων νεφρικων κυτταρων
EP1364652A4 (en) DRUGS FOR LUNG CANCER
UA96745C2 (en) PYRIDO-, PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
ATE445408T1 (de) Verwendung von prolactin in der prophylaktischen krebstherapie

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application